RIPK1 and amyotrophic lateral sclerosis: However, its broad kinase inhibition raises concerns about off-target effects, particularly in ALS models where kinases such as RIPK1 and EphA4 are implicated in neuroinflammation and axonal degeneration (Imamura et al., 2017).